Yes, XBP1 can contribute to resistance to [cancer therapies](href). By activating the UPR, XBP1 helps cancer cells survive under the stress induced by treatments such as chemotherapy and radiation. This resistance mechanism can make it challenging to eradicate cancer cells, leading to recurrence and treatment failure. Targeting XBP1 or its downstream signaling pathways may therefore enhance the efficacy of conventional therapies.
